Interpreting the CEPHEUS Data: Daratumumab-Based Therapy in Frontline Multiple Myeloma

Dr. Saad Usmani and Dr. Shaji Kumar introduce the evolving treatment landscape for newly diagnosed multiple myeloma, focusing on the increasing role of CD38-directed therapy in frontline treatment.

Dr. Saad Usmani and Dr. Shaji Kumar discuss how treatment goals and measures of clinical benefit have evolved in newly diagnosed multiple myeloma.

Dr. Saad Usmani reviews the design of the phase 3 CEPHEUS study in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma, highlighting the importance of patient fitness and age in defining the study population.

Dr. Saad Usmani and Dr. Shaji Kumar examine the CEPHEUS findings on response depth and durability in newly diagnosed multiple myeloma, with particular emphasis on MRD negativity and its potential implications for treatment duration.

Dr. Saad Usmani and Dr. Shaji Kumar discuss how sustained MRD negativity and long-term progression-free survival may inform future treatment strategies for patients with newly diagnosed multiple myeloma.

Dr. Saad Usmani and Dr. Shaji Kumar conclude the discussion by considering how the CEPHEUS findings may be applied to individual patients with newly diagnosed multiple myeloma.